Cercar

13/03/2026 Unveiling CMV Risk Signatures After Allogeneic Stem Cell Transplantation Through Machine Learning Approaches: A Multicenter Analysis From the GETH-TC
Giménez, E, Rodriguez-Belenguer, P, Solano, C, Vázquez, L, Martino, R, de la Cámara, R, Rovira, M, Espigado, I, Calvo, CM, López-Jiménez, J, Pérez, A, Bermúdez, A, Saldaña, R, Heras, I, González-Huerta, AJ, Torrado, T, Bautista, G, Perera-Alvarez, MD, González-Pinedo, L, Barba, P, Cuesta, MA, Chorao, P, Basalobre, P, Navarro, D, García-Cadenas, I, Piñana, JL. Unveiling CMV Risk Signatures After Allogeneic Stem Cell Transplantation Through Machine Learning Approaches: A Multicenter Analysis From the GETH-TC. JOURNAL OF MEDICAL VIROLOGY. 2026; 98(3)DOI:10.1002/jmv.70867. PMID:41823077. IF:4.600(Q1/1D).
01/02/2026 Outcomes of de novo primary central nervous system lymphoma using the MATRix regimen for induction followed by thiotepa-based conditioning: a GELTAMO analysis
Lopez-Pereira, P, Domínguez, SR, Martin-Moro, F, Caballero, AC, García, AL, Benito, BD, Sarto, MF, Vicente, FD, Marín, JL, Marino, SP, Jiménez-Ubieto, A, Cabirta, A, Gutiérrez, NC, Chulvi, MJL, Puyuelo, A, Prat, AM, Coello, AP, García-Lerma, E, Vilchez, SM. Outcomes of de novo primary central nervous system lymphoma using the MATRix regimen for induction followed by thiotepa-based conditioning: a GELTAMO analysis. BONE MARROW TRANSPLANTATION. 2026; 61(2)DOI:10.1038/s41409-025-02772-2. PMID:41310181. IF:5.200(Q1/1D).
01/03/2026 Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospects
Mur, P, Pozuelo, A, Tabernero, J, Albanell, J, Bellosillo, B, Bosch, F, Briones, J, Brunet, J, Colomer, D, Domènech, M, Fontanet, JM, Matias-Guiu, X, Salazar, R, Vivanco-Hidalgo, RM, Mollà, M, Moreno, L, Prat, A, Ribera, JM, Clèries, R, Guarga, A, Espinàs, JA, Borras, JM. Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospects. Clinical & Translational Oncology. 2026; 28(3)DOI:10.1007/s12094-025-04022-9. PMID:40900393. IF:2.500(Q3/6D).
01/03/2026 Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia
Mecklenbrauck, R, Ramiro, AV, Sträng, E, Gabdoulline, R, Elicegui, JM, Sobas, M, Pleyer, L, Turki, A, Voso, MT, Benner, A, Hernández-Sánchez, A, Tettero, JM, Gimenez, LT, Metzeler, KH, Oñate, G, Lehmann, S, Huntly, BJP, Thomas, I, Thol, FR, Heidel, FH, Valk, PJM, Döhner, K, Haferlach, T, Mills, KI, Döhner, H, Castellani, G, Ossenkoppele, GJ, Hernández-Rivas, JM, Bullinger, L, Heuser, M. Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia. LEUKEMIA. 2026; 40(3)DOI:10.1038/s41375-026-02874-w. PMID:41663622. IF:13.400(Q1/1D).
01/02/2026 Phase II Interim Results for Rapcabtagene Autoleucel (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma
Westin, J, Chavez, JC, Schuster, SJ, Vucinic, V, Young, PA, Johnson, PC, Bramanti, S, Rambaldi, A, Meijide, JB, Kato, K, Sancho, JM, Kwon, M, Solano, C, Fleming, S, Dahiya, S, García-Sancho, AM, Ramos, PM, Pearson, D, Diallo, S, Zia, A, Segura, E, Masood, A, Barba, P. Phase II Interim Results for Rapcabtagene Autoleucel (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma. Transplantation And Cellular Therapy. 2026; 32(2)DOI:. PMID:. IF:4.400(Q1/1D).
01/03/2026 The precision of a report on precision
Mur, P, Pozuelo, A, Tabernero, J, Albanell, J, Bellosillo, B, Bosch, F, Briones, J, Brunet, J, Colomer, D, Domènech, M, Fontanet, JM, Matias-Guiu, X, Salazar, R, Vivanco-Hidalgo, RM, Mollà, M, Moreno, L, Prat, A, Ribera, JM, Clèries, R, Guarga, A, Piñol, JAE, Borras, JM. The precision of a report on precision. Clinical & Translational Oncology. 2026; 28(3)DOI:10.1007/s12094-026-04219-6. PMID:41610006. IF:2.500(Q3/6D).
01/06/2023 Prehospital care process and hospital outcomes in stroke-code cases: comparison of basic and advance life support ambulance attendance
Munoz, SS, Campillo, MDE, Borrega, CS, Azeli, Y, Gil, SQ, Ruiz, A, Albacete, G, Peral, OM, Lluch, S, Delgado, SA, Blas, YS, Urra, X, Calderon, DC, Fabregas, JM, Jacobi, MR, Portela, PC, Garcia, FP, Oller, ED, Benitez, VH, Flores, A, Rubiera, M, Palomeras, E, Garcia-Tornel, A, Soler, RS, Roquet, DV, Salvat-Plana, M, Pachon, AR, Herrero, NPD, Fabrega, XJ. Prehospital care process and hospital outcomes in stroke-code cases: comparison of basic and advance life support ambulance attendance. EMERGENCIAS. 2023; 35(3)DOI:. PMID:37350599. IF:5.400(Q1/1D).
27/09/2024 Effects of Safinamide on Motor and Non-Motor Symptoms in Patients with Parkinson's Disease and Motor Fluctuations
Kulisevsky, J, Ferraz, HB, Suppa, A, Reichmann, H. Effects of Safinamide on Motor and Non-Motor Symptoms in Patients with Parkinson's Disease and Motor Fluctuations. EUROPEAN NEUROLOGY. 2024; 87(5-6)DOI:10.1159/000541362. PMID:39342935. IF:2.400(Q3/6D).
07/02/2024 Combining mindfulness and cognitive training in children with attention deficit hyperactivity disorder: study protocol of a pilot randomized controlled trial (the NeuroMind study)
Badia-Aguarón, T, Royuela-Colomer, E, Pera-Guardiola, V, Vergés-Balasch, P, Cebolla, A, Luciano, JV, Soler, J, Feliu-Soler, A, Miguel, AH. Combining mindfulness and cognitive training in children with attention deficit hyperactivity disorder: study protocol of a pilot randomized controlled trial (the NeuroMind study). Frontiers in Psychology. 2024; 15DOI:10.3389/fpsyg.2024.1291198. PMID:38384348. IF:2.900(Q1/3D).
01/10/2024 Assessing the Impact of the Way of Saint James on Psychological Distress and Subjective Well-being: The Ultreya Study
Feliu-Soler, A, Royuela-Colomer, E, Navarrete, J, Jorgensen, NN, Mariño, M, Demarzo, M, Soler, J, García-Campayo, J, Montero-Marín, J, Luciano, JV. Assessing the Impact of the Way of Saint James on Psychological Distress and Subjective Well-being: The Ultreya Study. Journal of Happiness Studies. 2024; 25(7)DOI:10.1007/s10902-024-00820-0. PMID:. IF:3.300(Q1/1D).
01/10/2022 Characteristics of subjective cognitive decline associated with amyloid positivity
Janssen, O, Jansen, WJ, Vos, SJB, Boada, M, Parnetti, L, Gabryelewicz, T, Fladby, T, Molinuevo, JL, Villeneuve, S, Hort, J, Epelbaum, S, Lleo, A, Engelborghs, S, van der Flier, WM, Landau, S, Popp, J, Wallin, A, Scheltens, P, Rikkert, MO, Snyder, PJ, Rowe, C, Chetelat, G, Ruiz, A, Marquie, M, Chipi, E, Wolfsgruber, S, Heneka, M, Boecker, H, Peters, O, Jarholm, J, Rami, L, Tort-Merino, A, Binette, AP, Poirier, J, Rosa-Neto, P, Cerman, J, Dubois, B, Teichmann, M, Alcolea, D, Fortea, J, Sanchez-Saudinos, MB, Ebenau, J, Pocnet, C, Eckerstrom, M, Thompson, L, Villemagne, V, Buckley, R, Burnham, S, Delarue, M, Freund-Levi, Y, Wallin, AK, Ramakers, I, Tsolaki, M, Soininen, H, Hampel, H, Spiru, L, Tijms, B, Ossenkoppele, R, Verhey, FRJ, Jessen, F, Visser, PJ. Characteristics of subjective cognitive decline associated with amyloid positivity. ALZHEIMERS & DEMENTIA. 2022; 18(10)DOI:10.1002/alz.12512. PMID:34877782. IF:14.000(Q1/1D).
13/03/2024 Adapting prescribing criteria for amyloid-targeted antibodies for adults with Down syndrome
Hillerstrom, H, Fisher, R, Janicki, MP, Chicoine, B, Christian, BT, Esbensen, A, Esralew, L, Fortea, J, Hartley, S, Hassenstab, J, Keller, SM, Krinsky-McHale, S, Lai, FRC, Levin, J, Mccarron, M, Mcdade, E, Rebillat, AS, Rosas, HD, Silverman, W, Strydom, A, Zaman, SH, Zetterberg, H. Adapting prescribing criteria for amyloid-targeted antibodies for adults with Down syndrome. ALZHEIMERS & DEMENTIA. 2024; 20(5)DOI:10.1002/alz.13778. PMID:38480678. IF:11.100(Q1/1D).
01/03/2026 Subphenotype-and complication-guided adjunctive fosfomycin versus standard monotherapy in Staphylococcus aureus bacteraemia: pooled analysis of two randomised trials
Escrihuela-Vidal, F, Larrauri, JG, López-Contreras, J, Euba, G, Vázquez, A, Gómez-Zorrilla, S, López-Cortés, LE, Gasch, O, Aparicio-Minguijón, E, Escudero-Sànchez, R, Pérez-Rodríguez, MT, Rodríguez-Pardo, D, Jover-Sáenz, A, García-Pardo, G, Rodríguez-Baño, J, Pujol, M, Carratalà, J, Gutiérrez-Gutiérrez, B. Subphenotype-and complication-guided adjunctive fosfomycin versus standard monotherapy in Staphylococcus aureus bacteraemia: pooled analysis of two randomised trials. Lancet Regional Health-Europe. 2026; 62DOI:10.1016/j.lanepe.2026.101611. PMID:41788427. IF:13.000(Q1/1D).
15/02/2026 Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials
Escrihuela-Vidal, F, Ong, SWX, Oriol, I, Grillo, S, Pujol, M, Pallarès, N, Tebé, C, Liu, K, Miro, JM, Tong, SYC, Carratalà, J. Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials. CLINICAL INFECTIOUS DISEASES. 2026; 82(2)DOI:10.1093/cid/ciaf387. PMID:40670317. IF:7.300(Q1/1D).
01/02/2026 The role of artificial intelligence in predicting graft survival in kidney transplantation: a systematic review
Di Bello, F, Gallioli, A, Pecoraro, A, Prudhomme, T, Piana, A, Marco, BB, Haberal, HB, Dönmez, MI, Lopez-Abad, A, Cannoletta, D, Mancon, S, Guirado, L, Facundo, C, Kanashiro, AK, Gavrilov, P, Rodriguez-Faba, O, Gaya, JM, Breda, A, Territo, A. The role of artificial intelligence in predicting graft survival in kidney transplantation: a systematic review. Minerva Urology And Nephrology. 2026; 78(1)DOI:10.23736/S2724-6051.25.06559-0. PMID:41697205. IF:4.200(Q1/2D).
01/02/2026 Risk factors associated with inadequacy of empirical treatment in patients with sepsis and bacteremia attended in an emergency department
Motos-Bescós, M, Ruiz-Ramos, J, Agra-Montava, I, Moliné-Pareja, A, Palacio-Alvarez, P, Villarejo-Jiménez, A, Pomar-Solchaga, V. Risk factors associated with inadequacy of empirical treatment in patients with sepsis and bacteremia attended in an emergency department. Revista Espanola de Quimioterapia. 2026; 39(1)DOI:10.37201/req/101.2025. PMID:41521957. IF:2.200(Q3/6D).
01/12/2024 Ciprofloxacin for the Treatment of Infections Caused by Carbapenemase-Producing Gram-Negative Bacteria
Rubinan, P, Viñado, B, Fernández-Hidalgo, N, Larrosa, N, Sempere, A, Campany, D, Rodríguez-Pardo, D, González-López, JJ, Nuvials, X, del Barrio-Tofiño, E, Escolà-Vergé, L, Los-Arcos, I. Ciprofloxacin for the Treatment of Infections Caused by Carbapenemase-Producing Gram-Negative Bacteria. Antibiotics-Basel. 2024; 13(12)DOI:10.3390/antibiotics13121138. PMID:39766528. IF:4.600(Q1/2D).
21/02/2026 Adequacy of the Type of Venous Catheter to the Drug Type and Duration of Treatment: A Cross-Sectional Study
Moreno-Rubio, E, Pérez-López, C, Carmezim, J, Blancas-Altabella, D, Simonetti, AF, Sanchez, SS, Rodríguez-Molinero, A. Adequacy of the Type of Venous Catheter to the Drug Type and Duration of Treatment: A Cross-Sectional Study. Nursing Reports. 2026; 16(2)DOI:10.3390/nursrep16020076. PMID:41745901. IF:(Q/D).
01/08/2024 Characterization of white matter hyperintensities in Down syndrome
Morcillo-Nieto, AO, Zsadanyi, SE, Arriola-Infante, JE, Carmona-Iragui, M, Montal, V, Pegueroles, J, Aranha, MR, Vaque-Alcazar, L, Padilla, C, Benejam, B, Videla, L, Barroeta, I, Fernandez, S, Altuna, M, Gimenez, S, Gonzalez-Ortiz, S, Bargallo, N, Ribas, L, Arranz, J, Torres, S, Iulita, MF, Belbin, O, Camacho, V, Alcolea, D, Lleo, A, Fortea, J, Bejanin, A. Characterization of white matter hyperintensities in Down syndrome. ALZHEIMERS & DEMENTIA. 2024; 20(9)DOI:10.1002/alz.14146. PMID:39087352. IF:11.100(Q1/1D).
26/03/2024 Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
Ospina, AV, Nadal, SB, de la Cruz, JLCC, Larriba, JLG, Vidueira, IM, Sureda, BM, Nadal, E, Trancho, FH, Kindelan, AA, Morillo, E, Caro, RB, Barrera, JB, de Juan, VC, Rubio, JC, de Castro, J, Ramos, AC, Dols, MC, Gomez, M, Almanzar, S, Campelo, RG, Molla, AI, Sarceda, JRJ, Maestre, UJ, Castro, RL, Majem, M, Martinez-Marti, A, Tellez, EM, Lorente, DS, Provencio, M. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP. Clinical & Translational Oncology. 2024; DOI:10.1007/s12094-024-03382-y. PMID:38530556. IF:2.500(Q3/6D).